Correction to: npj Breast Cancerhttps://doi.org/10.1038/s41523-024-00657-z, published online 17 July 2024 In this article, the affiliation details for Giuseppe Curigliano were incorrectly given as “12Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy” but should have been ‘12Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy’, ‘13Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy’ and for, Carmen Criscitiello were incorrectly given as ‘13Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy’ but should have been ‘12Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy’, ‘13Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy’. The original article has been corrected.

Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z) / Scagnoli, S.; Pisegna, S.; Toss, A.; Caputo, R.; De Laurentiis, M.; Palleschi, M.; de Giorgi, U.; Cortesi, E.; Fabbri, A.; Fabi, A.; Paris, I.; Orlandi, A.; Curigliano, G.; Criscitiello, C.; Garrone, O.; Tomasello, G.; D'Auria, G.; Vici, P.; Ricevuto, E.; Domati, F.; Piombino, C.; Parola, S.; Scafetta, R.; Cirillo, A.; Taurelli Salimbeni, B.; Di Lisa, F. S.; Strigari, L.; Preissner, R.; Simmaco, M.; Santini, D.; Marchetti, P.; Botticelli, A.. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - 10:1(2024), pp. 1-1. [10.1038/s41523-024-00682-y]

Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z)

Toss A.;Domati F.;Piombino C.;
2024

Abstract

Correction to: npj Breast Cancerhttps://doi.org/10.1038/s41523-024-00657-z, published online 17 July 2024 In this article, the affiliation details for Giuseppe Curigliano were incorrectly given as “12Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy” but should have been ‘12Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy’, ‘13Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy’ and for, Carmen Criscitiello were incorrectly given as ‘13Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy’ but should have been ‘12Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy’, ‘13Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy’. The original article has been corrected.
2024
10
1
1
1
Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z) / Scagnoli, S.; Pisegna, S.; Toss, A.; Caputo, R.; De Laurentiis, M.; Palleschi, M.; de Giorgi, U.; Cortesi, E.; Fabbri, A.; Fabi, A.; Paris, I.; Orlandi, A.; Curigliano, G.; Criscitiello, C.; Garrone, O.; Tomasello, G.; D'Auria, G.; Vici, P.; Ricevuto, E.; Domati, F.; Piombino, C.; Parola, S.; Scafetta, R.; Cirillo, A.; Taurelli Salimbeni, B.; Di Lisa, F. S.; Strigari, L.; Preissner, R.; Simmaco, M.; Santini, D.; Marchetti, P.; Botticelli, A.. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - 10:1(2024), pp. 1-1. [10.1038/s41523-024-00682-y]
Scagnoli, S.; Pisegna, S.; Toss, A.; Caputo, R.; De Laurentiis, M.; Palleschi, M.; de Giorgi, U.; Cortesi, E.; Fabbri, A.; Fabi, A.; Paris, I.; Orland...espandi
File in questo prodotto:
File Dimensione Formato  
s41523-024-00682-y.pdf

Open access

Tipologia: VOR - Versione pubblicata dall'editore
Dimensione 435.19 kB
Formato Adobe PDF
435.19 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1367667
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact